NASDAQ:VRPX Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis → Wall Street Icon: 'I'd Put 50% of My Kids' Inheritance in THIS stock' (From Stansberry Research) (Ad) Free VRPX Stock Alerts $0.71 -0.01 (-1.39%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.7350-Day Range$0.70▼$4.0952-Week Range$0.63▼$11.77Volume20,914 shsAverage Volume61,280 shsMarket Capitalization$830,700.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Virpax Pharmaceuticals alerts: Email Address Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.Read More VRPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRPX Stock News HeadlinesMay 29, 2024 | businesswire.comVirpax® Pharmaceuticals to Present at 2024 BIO International ConventionMay 23, 2024 | msn.comMaxim Group Downgrades Virpax Pharmaceuticals (VRPX)May 18, 2024 | uk.investing.comVirpax Pharmaceuticals sets terms for $2.25 million offeringMay 16, 2024 | wsj.comVirpax Pharmaceuticals Inc.May 15, 2024 | marketwatch.comVirpax Pharmaceuticals Shares Hit All-Time Low After Equity SaleMay 15, 2024 | investorplace.comWhy Is Virpax Pharmaceuticals (VRPX) Stock Down 61% Today?May 15, 2024 | businesswire.comVirpax Announces Pricing of $2.25 Million Public OfferingMay 14, 2024 | investorplace.comVRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q1 2024May 13, 2024 | businesswire.comVirpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsMay 8, 2024 | msn.comVirpax Pharmaceuticals' Probudur Shows Promising Results in Pain Management StudyApril 30, 2024 | businesswire.comVirpax Announces Results of Maximum Tolerated Dose Study for Probudur™April 24, 2024 | investorplace.comVRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023April 2, 2024 | msn.comVirpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management SolutionsMarch 26, 2024 | businesswire.comVirpax Pharmaceuticals Reports 2023 Year-End ResultsFebruary 27, 2024 | finance.yahoo.comVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid PriceFebruary 27, 2024 | businesswire.comVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid PriceFebruary 27, 2024 | businesswire.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 12, 2024 | msn.comVirpax Pharmaceuticals Reports Promising Results in Probudur Pilot StudyFebruary 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)February 7, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)January 23, 2024 | investing.comVirpax Pharmaceuticals Inc (VRPX)December 29, 2023 | msn.comVirpax Pharmaceuticals shareholders okay reverse stock splitDecember 28, 2023 | msn.comTitan Pharmaceuticals to conduct 1-for-20 reverse stock splitNovember 22, 2023 | seekingalpha.comVRPX Virpax Pharmaceuticals, Inc.November 18, 2023 | markets.businessinsider.comPromising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax PharmaceuticalsSee More Headlines Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/12/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VRPX CUSIPN/A CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-345.87% Return on Assets-161.82% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book0.43Miscellaneous Outstanding Shares1,170,000Free Float1,098,000Market Cap$830,700.00 OptionableNot Optionable Beta1.23 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Gerald W. Bruce (Age 67)CEO & Director Comp: $371.87kMr. Vinay Shah A.C.A. (Age 61)M.B.A., CFO, Principal Financial Officer, Principal Accounting Officer & Corporate Secretary Comp: $238kDr. Sheila A. Mathias J.D. (Age 56)M.B.A., Ph.D., Chief Scientific Officer Comp: $698.97kMs. Shana PanzarellaChief of StaffKey CompetitorsSoligenixNASDAQ:SNGXAvenue TherapeuticsNASDAQ:ATXIAridis PharmaceuticalsNASDAQ:ARDSSonoma PharmaceuticalsNASDAQ:SNOAAyala PharmaceuticalsNASDAQ:ADXSView All Competitors VRPX Stock Analysis - Frequently Asked Questions Should I buy or sell Virpax Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Virpax Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VRPX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRPX, but not buy additional shares or sell existing shares. View VRPX analyst ratings or view top-rated stocks. How have VRPX shares performed in 2024? Virpax Pharmaceuticals' stock was trading at $3.2010 on January 1st, 2024. Since then, VRPX stock has decreased by 77.8% and is now trading at $0.71. View the best growth stocks for 2024 here. Are investors shorting Virpax Pharmaceuticals? Virpax Pharmaceuticals saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 56,700 shares, a decline of 28.8% from the May 15th total of 79,600 shares. Based on an average trading volume of 98,600 shares, the short-interest ratio is presently 0.6 days. Approximately 2.8% of the shares of the stock are sold short. View Virpax Pharmaceuticals' Short Interest. When is Virpax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our VRPX earnings forecast. How were Virpax Pharmaceuticals' earnings last quarter? Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) issued its quarterly earnings data on Monday, May, 13th. The company reported ($2.75) EPS for the quarter. When did Virpax Pharmaceuticals' stock split? Virpax Pharmaceuticals shares reverse split on the morning of Friday, March 1st 2024. The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virpax Pharmaceuticals IPO? Virpax Pharmaceuticals (VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRPX) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredPlease, take this warning seriously todayWall Street Legend Warns "Mass Bank Run" is Coming Man who predicted 2023 bank run warns it could soon get ...Chaikin Analytics | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
